Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
IJJP pinksheets update
Outstanding Shares
21,530,000 as of Jul 31, 2009
BBAN 0005/0006
OPGX big blocks going too
OPGX 0005s almost gone
.0005s getting tore up
NSEO - 1 Left at 0003
OPXA Going Nuts
Opexa Announces Stem Cell Agreement with Leading Global Pharmaceutical Company
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing a novel T-cell immunotherapy for multiple sclerosis (MS), today announced that it has entered into an exclusive agreement with Novartis, one of the world's largest pharmaceutical companies, for the further development of Opexa's novel stem cell technology. This technology, which has generated preliminary data showing the potential to generate monocyte derived islet cells from peripheral blood mononuclear cells, was in early preclinical development at Opexa.
Under the terms of the agreement, Novartis will acquire the stem cell technology from Opexa and Novartis will have full responsibility for funding and carrying out all research, development and commercialization activities. Opexa will receive an upfront cash payment of $3 million, plus an additional $1 million as a technology transfer fee to be paid over the course of a six month period. Total payments to Opexa, including the upfront payment, the technology transfer fee and development and commercial milestone payments could exceed $50 million not including royalties. Opexa is also eligible to receive royalty payments from the sale of any products resulting from the use of the technology and retains an option on certain manufacturing rights.
"This represents a great opportunity for Opexa," stated Neil K. Warma, Opexa's president and chief executive officer. "Novartis is one of the premier pharmaceutical companies and the expertise they bring to this program will undoubtedly advance the technology significantly. This agreement will also allow us to firmly focus our attention on our key clinical asset, Tovaxin(R).
About Opexa
Opexa Therapeutics, Inc. is dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases. The Company's leading therapy, Tovaxin, is an individualized cellular immunotherapy treatment in Phase IIb clinical development for Multiple Sclerosis (MS). Tovaxin is derived from T-cells isolated from peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin and, thereby, reduces the risk of relapse over time. Data from the first Phase IIb clinical study showed compelling evidence that Relapsing Remitting MS patients treated with Tovaxin saw overall clinical, MRI, and immunological benefits over the placebo group, including statistical significance for decrease in the Annualized Relapse Rate (ARR), improvement in disability score (EDSS), and improvement in quality of life measures (MSQLI), as well as an excellent safety profile with no serious adverse events related to Tovaxin treatment.
For more information visit the Opexa Therapeutics website at www.opexatherapeutics.com
Already up to 1.8x
Outstanding Call!
SARO, News before the bell, "FasTech's CTO to Develop and Implement Its Control and Monitoring Technologies"
BBAN 0004/0009: Mexican Standoff
Grabbed some 01s here.. like how easy this has been moving
ICTY Hits at 0007 , looking for a green close
NSEO - 0004 Prints
ICTY - Record volume day #2
BBAN 0006/0007 - Down 2 ticks on a Whack
SARO 0011/0012
PPJE 1 @ .018
ICTY 0008/0009 - Go for another leg this afternoon
SARO 0007/0008 Ask has been getting hit today
NESO 0003/0004 back up
NSEO - Lunctime Dip? 77% Buys
ICTY 0011/0012
ICTY - Liking this pick
LDSR - Got out before it sank, heck of a ride
LDSR 0025 getting hit
LDSR 0019/002 - Happy Dance
LDSR - 0016/0017 - My Goodness
LDSR 0014x0015 - Ask Pounding
LDSR 0013x0014
LDSR 0011x0012
LDSR 001 getting taken down
Kick butt calls 911
LDSR 0009x001
LDSR hitting 0009s
LDSR 1 left @ 0008
Close at HOD on big volume
thanks for posting your TA DD
LCRE, Did you catch this article?
http://www.businesswire.com/portal/site/home/permalink/?ndmViewId=news_view&newsId=20090330005416&newsLang=en
LCRE 003x0032
6 MMs on the ask over .01
LCRE 0025/0026